The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

Figure 1: Nuclear receptor co-regulators modulate the transcriptional potential of estrogen receptor activated ... ER signaling pathways to confer a selective advantage in tumor progression.

U is a selective estrogen receptor degrader (Selective estrogen receptor degraders (SERDs)) that is being evaluated as a once-daily oral treatment for patients with estrogen receptor-positive (ER+ ...

The Fatima bint Mubarak Center at Cleveland Clinic Abu Dhabi, part of the M42 group, becomes the first center in the GCC ...

This is a new kind of oral selective estrogen receptor degrader (SERD), used to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast ...

The EMBER-3 study introduced imlunestrant, an oral selective estrogen receptor degrader (SERD), as a potential treatment for hormone receptor–positive, HER2-negative metastatic breast cancer ...

Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.

Live webcasts of these presentations will be available in the Events and Presentations section of Olema’s investor relations website at ir.olema.com. The webcasts will be archived for at least 30 days ...

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...

Morgan Stanley analyst Michael Ulz has maintained their neutral stance on ZNTL stock, giving a Hold rating yesterday.Invest with Confidence: ...